Synaptrix, a spin-out medical device company, is focused on developing and commercializing drug-free, long-lasting solutions for post-operative pain management. Our proprietary NOVABLOC™ system is a procedure-based solution that delivers a novel type of electrical stimulation to selectively blocks pain signal transmission. Through human feasibility studies we have demonstrated 10+ days of pain relief with a single treatment, while sparing motor function, touch and proprioception. Synaptrix plans to receive FDA clearance in 2024 and begin commercialization of the NOVABLOC™ system in 2025.